Barclays Maintains Underweight on Celldex Therapeutics, Raises Price Target to $24
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Underweight and raises the price target from $21 to $24.
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Underweight and raises the price target from $21 to $24.